Workflow
Endovastec(688016)
icon
Search documents
心脉医疗(688016) - 2019 Q3 - 季度财报
2019-10-27 16:00
Financial Performance - Operating revenue for the first nine months was ¥247,585,761.67, representing a 43% increase from ¥172,870,887.38 in the same period last year[18]. - Net profit attributable to shareholders of the listed company was ¥112,533,389.88, up 48% from ¥76,085,508.42 year-over-year[18]. - The company's net profit increased by 152% to CNY 149,273,681.15 compared to CNY 59,240,291.27 in the previous year[33]. - Total revenue for Q3 2019 reached ¥75,640,622.36, a 47.0% increase from ¥51,473,511.71 in Q3 2018[52]. - Net profit for Q3 2019 was ¥27,520,129.08, up 76.5% from ¥15,594,305.49 in Q3 2018[55]. - The company reported a total profit of CNY 32,551,115.32 for the quarter, up from CNY 18,315,493.86 in the same period last year, an increase of 77.5%[64]. Assets and Liabilities - Total assets at the end of the reporting period reached ¥1,112,608,982.52, an increase of 314% compared to the previous year's end[18]. - The company's total assets reached RMB 1.11 billion, a substantial increase from RMB 268.82 million in the previous year[40]. - Total liabilities increased to ¥75,580,491.14 from ¥52,657,501.31, marking a 43.4% rise[51]. - The company's total liabilities increased by 33% to CNY 8,277,468.39, driven by higher procurement scale[32]. - The equity attributable to shareholders was RMB 1.04 billion, significantly up from RMB 216.16 million, indicating a growth of over 380%[41]. Cash Flow - The net cash flow from operating activities for the first nine months was ¥110,905,645.53, a 38% increase compared to ¥80,157,960.05 in the previous year[18]. - Cash inflow from operating activities totaled 294,252,332.26 RMB, up from 205,443,698.25 RMB in the same period last year, representing an increase of approximately 43%[69]. - The ending balance of cash and cash equivalents reached 859,320,878.97 RMB, up from 30,910,905.35 RMB year-over-year[72]. - The company reported a significant increase in cash received from sales of goods and services, amounting to 278,613,095.05 RMB, compared to 195,684,853.57 RMB in the previous year[75]. Shareholder Information - The total number of shareholders at the end of the reporting period was 12,115, with the largest shareholder holding 45.71% of the shares[26]. - The diluted earnings per share for the reporting period was ¥1.94, which is a 38% increase from ¥1.41 in the same period last year[20]. Research and Development - Research and development expenses rose by 68% to CNY 29,511,429.09, indicating increased investment in R&D projects[33]. - Research and development expenses for Q3 2019 were ¥10,610,722.59, up from ¥5,994,293.60 in Q3 2018, representing a 77.5% increase[52].